SuperworthIradimed IRMD
- Market cap
- $1.1B
- PE
- 47.9×
- 10y median 41.4×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 12.7×
- EV/EBIT
- 37.7×
- Revenue, 12 months
- $86.3M
- +11% on a year ago
- Net margin
- 26.7%
- Free cash flow yield
- 2.3%
Iradimed trades at 47.9× trailing earnings, near its ten-year median. Revenue was $86.3M over the last twelve months, up 11% on a year earlier with a 27% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $16.5M+23% | $17.5M+17% | $17.6M+14% | $17.9M+11% | $18.3M+11% | $19.4M+11% | $19.5M+11% | $20.4M+14% | $21.2M+16% | $22.7M+17% | $22M+13% | $20.5M+0% | |
| Cost of revenue | $3.7M+28% | $4M+11% | $4.2M+12% | $3.9M−1% | $4.1M+13% | $4.6M+15% | $4.7M+11% | $4.5M+14% | $4.7M+14% | $5.7M+22% | $5.2M+11% | $5.3M+19% |
| Gross profit | $12.8M+22% | $13.4M+20% | $13.4M+14% | $14M+15% | $14.2M+11% | $14.8M+10% | $14.8M+11% | $16M+14% | $16.5M+16% | $17M+15% | $16.8M+13% | $15.2M−5% |
| R&D | $452.6K−8% | $650.4K+8% | $821K−73% | $801.1K−17% | $639.5K+41% | $570K−12% | $624.2K−24% | $877.4K+10% | $674.4K+6% | $799K+40% | $956K+53% | $657K−25% |
| SG&A | $6.5M+10% | $7.6M+20% | $7.8M+66% | $7.6M+21% | $7.8M+20% | $8.4M+10% | $8.8M+12% | $8.3M+9% | $9M+16% | $9.1M+9% | $8.6M−2% | $8.1M−2% |
| $5.9M+43% | $5.2M+21% | $4.7M+19% | $5.6M+13% | $5.8M−2% | $5.8M+12% | $5.4M+14% | $6.8M+21% | $6.8M+18% | $7.1M+22% | $7.2M+33% | $6.4M−6% | |
| Pre-tax income | $6.4M+51% | $5.7M+21% | $5.2M+21% | $6.3M+18% | $6.4M+0% | $6.3M+12% | $5.9M+13% | $7.3M+17% | $7.3M+14% | $7.8M+23% | $7.8M+31% | $6.9M−6% |
| $1.3M+66% | $1.1M+11% | $1.1M+17% | $1.4M+22% | $1.4M+2% | $1.2M+5% | $1.3M+14% | $1.6M+14% | $1.7M+26% | $1.3M+13% | $2M+55% | $1.7M+8% | |
| Net income | $5.1M+48% | $4.5M+24% | $4.1M+21% | $4.9M+17% | $5M−0% | $5.1M+13% | $4.7M+13% | $5.8M+18% | $5.6M+10% | $6.4M+25% | $5.8M+24% | $5.2M−10% |
| $0.40+48% | $0.36+24% | $0.32+19% | $0.38+15% | $0.40+0% | $0.40+11% | $0.37+16% | $0.45+18% | $0.43+8% | $0.50+25% | $0.45+22% | $0.41−9% | |
| 12.7M+1% | 12.7M+1% | 12.7M+1% | 12.8M+0% | 12.8M+0% | 12.8M+1% | 12.8M+1% | 12.8M+1% | 12.9M+1% | 12.9M+0% | 12.9M+0% | 12.9M+0% |
Revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Income tax: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 15 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Iradimed's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| Peer median | $1.3B | 30.1× | 38.9× | 2.0× | +8% | 6.5% |
More on Iradimed
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .